

10. Mendelssohn DC. Coping with the CKD epidemic: the promise of multidisciplinary team-based care. *Nephrol Dial Transplant* 2005; 20: 10–12
11. Lin CL, Wu MS, Hsu PY *et al.* Improvement of clinical outcome by early nephrology referral in type II diabetics on hemodialysis. *Ren Fail* 2003; 25: 455–464
12. Schwenger V, Morath C, Hofmann A *et al.* Late referral—a major cause of poor outcome in the very elderly dialysis patient. *Nephrol Dial Transplant* 2006; 21: 962–967
13. Wu MS, Lin CL, Chang CT *et al.* Improvement in clinical outcome by early nephrology referral in type II diabetics on maintenance peritoneal dialysis. *Perit Dial Int* 2003; 23: 39–45
14. ERA-EDTA Registry. Appendix 1. *ERA-EDTA Registry Annual Report 2007*. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics, 2009; 126
15. Khan IH, Catto GR, Edward N *et al.* Influence of coexisting disease on survival on renal-replacement therapy. *Lancet* 1993; 341: 415–418
16. Detsky AS, McLaughlin JR, Baker JP *et al.* What is subjective global assessment of nutritional status? *J Parenter Enteral Nutr* 1987; 11: 8–13
17. Visser R, Dekker FW, Boeschoten EW *et al.* Reliability of the 7-point subjective global assessment scale in assessing nutritional status of dialysis patients. *Adv Perit Dial* 1999; 15: 222–225
18. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. *Am J Clin Nutr* 1980; 33: 27–39
19. Bergstrom J, Heimbürger O, Lindholm B. Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? *Perit Dial Int* 1998; 18: 467–473
20. Skrondal A. Interaction as departure from additivity in case-control studies: a cautionary note. *Am J Epidemiol* 2003; 158: 251–258
21. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. *Epidemiology* 1992; 3: 452–456
22. de Mutsert R., Jager KJ, Zoccali C *et al.* The effect of joint exposures: examining the presence of interaction. *Kidney Int* 2009; 75: 677–681
23. Avorn J, Bohn RL, Levy E *et al.* Nephrologist care and mortality in patients with chronic renal insufficiency. *Arch Intern Med* 2002; 162: 2002–2006
24. Jungers P, Massy ZA, Nguyen-Khoa T *et al.* Longer duration of pre-dialysis nephrological care is associated with improved long-term survival of dialysis patients. *Nephrol Dial Transplant* 2001; 16: 2357–2364
25. Kinchen KS, Sadler J, Fink N *et al.* The timing of specialist evaluation in chronic kidney disease and mortality. *Ann Intern Med* 2002; 137: 479–486
26. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. *BMC Nephrol* 2008; 9: 3
27. Arora P, Obrador GT, Ruthazer R *et al.* Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. *J Am Soc Nephrol* 1999; 10: 1281–1286
28. Jungers P, Zingraff J, Albouze G *et al.* Late referral to maintenance dialysis: detrimental consequences. *Nephrol Dial Transplant* 1993; 8: 1089–1093
29. Mendelssohn DC, Malmberg C, Hamandi B. An integrated review of “unplanned” dialysis initiation: reframing the terminology to “sub-optimal” initiation. *BMC Nephrol* 2009; 10: 22
30. de Mutsert R., Grootendorst DC, Boeschoten EW *et al.* Subjective global assessment of nutritional status is strongly associated with mortality in chronic dialysis patients. *Am J Clin Nutr* 2009; 89: 787–793
31. Jansen MA, Hart AA, Korevaar JC *et al.* Predictors of the rate of decline of residual renal function in incident dialysis patients. *Kidney Int* 2002; 62: 1046–1053

Received for publication: 28.9.09; Accepted in revised form: 30.6.10

*Nephrol Dial Transplant* (2011) 26: 658–664

doi: 10.1093/ndt/gfq411

Advance Access publication 14 July 2010

## Serum IL-6, albumin and comorbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis

Kuo-Chin Hung<sup>1,\*</sup>, Chia-Chao Wu<sup>2,\*</sup>, Hsiao-Shuang Chen<sup>1</sup>, Wen-Ya Ma<sup>1</sup>, Chin-Feng Tseng<sup>1</sup>, Lai-King Yang<sup>1</sup>, Hsiang-Li Hsieh<sup>3</sup> and Kuo-Cheng Lu<sup>1</sup>

<sup>1</sup>Department of Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, Taipei, Taiwan, Republic of China,

<sup>2</sup>Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China and <sup>3</sup>Department of Nursing, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, Taipei, Taiwan, Republic of China

Correspondence and offprint requests to: Kuo-Cheng Lu; E-mail: corey926@gmail.com

\*These authors have equal contribution to this work.

### Abstract

**Background.** Depression may be associated with activation of pro-inflammatory cytokines and increased long-term mortality in patients on maintenance haemodialysis (MHD).

There are numerous reports regarding the association of depression with inflammatory status, co-morbidities and nutritional condition, but few of these studies have explored the possible correlations between depression, age and

economic status. The study explores the possible correlations between depression and demographic, socio-economic, clinical and laboratory variables.

**Methods.** One hundred and forty-six MHD patients (65 males and 81 females, mean age:  $63.8 \pm 15.2$  years) were enrolled in this cross-sectional study. Demographic and socio-economic status as well as clinical and laboratory variables including co-morbidities were obtained. The self-administered Beck Depression Inventory (BDI) was used to determine the presence or absence of depression symptoms. Biochemical parameters (serum albumin, triglyceride, cholesterol, etc.) and dialysis dosage delivery (Kt/V and urea reduction rate or URR) were examined. All the patients were on high-flux biocompatible dialysers for MHD. The presence of an inflammatory state was assessed by determinations of plasma interleukin-6 (IL-6) levels.

**Results.** The prevalence of depression (BDI  $\geq 14$ ) was 45.9%. In patients found to have symptoms of depression, no statistically significant difference was shown with respect to age, gender, smoking habits or clinical characteristics. However, these patients were more likely to have a number of co-morbidities. They also had higher levels of serum IL-6 and total cholesterol as well as lower serum albumin and Kt/V values. The BDI correlated significantly with Kt/V values ( $r = -0.19$ ;  $P < 0.05$ ), levels of serum albumin ( $r = -0.28$ ;  $P < 0.005$ ) and serum IL-6 ( $r = 0.47$ ;  $P < 0.001$ ). Multivariate stepwise forward logistic regression analysis showed a direct correlation between BDI and IL-6 levels ( $P = 0.001$ ; OR = 1.537) and between BDI and co-morbidities ( $P = 0.037$ ; OR = 3.584). There was an inverse correlation between BDI and serum albumin levels ( $P = 0.006$ ; OR = 0.145) and between BDI and age ( $P = 0.007$ ; OR = 0.96). The rate of depression was significantly lower for the elderly patients (age  $\geq 75$  years) compared with those below 64 years of age. The percentage of personal monthly disposable income at or above Taiwan dollar (TWD)  $>10\,000$  was similar in patients aged  $\geq 75$  and those below 64 years old.

**Conclusions.** Maintenance haemodialysis patients with symptoms of depression may have higher serum IL-6 and lower serum albumin levels. The prevalence of depression was lower in elderly patients at or above 75 years old, and no correlation was found with socio-economic status. Factors including co-morbid conditions, serum IL-6, albumin and age may help predict which patients may be predisposed to develop symptoms of depression.

**Keywords:** age; depression; haemodialysis; IL-6; Kt/V

## Introduction

Depression is common in patients with end-stage renal disease on maintenance haemodialysis (MHD), with prevalence rates ranging between 30% and 60%. As is known in the general population as well as in people suffering from chronic diseases, there is evidence that depression is associated with mortality in MHD patients [1,2]. To date, possible theoretical explanations reported [3,4] include physical and emotional stress related to dietary constraints, time restrictions, functional limitations, co-morbidities and adverse effects of medi-

cations [5–7]. In addition, lack of adherence to dialysis treatment and its efficacy as well as hyperparathyroidism, malnutrition, chronic inflammation and elevated plasma cytokine levels may all have a significant role in bringing about symptoms of depression.

Previous studies have shown that activation of pro-inflammatory cytokines such as interleukin-6 (IL-6) or C-reactive protein (CRP) may be involved in the development of symptoms of depression in patients with end-stage renal disease (ESRD) [8–10]. However, apart from the correlations between depression and a number of socio-demographic characteristics, little is known about the clinical and laboratory variables (including inflammation markers such as IL-6) that may be associated with symptoms of depression in MHD patients [11].

Identification of the possible causative factors in the development of depression may allow medical providers to come up with adequate therapeutic strategies. However, few studies have evaluated the possible correlations of depression with problems inherent in ESRD patients, namely a state of chronic inflammation, the presence of co-morbidities and the nutritional status. In addition, none of these studies has examined the potential impact of age and personal disposable income as well, given the fact that the cost of MHD is fully covered by the Taiwan Bureau of National Health Insurance [12]. The present study investigates the correlations between depression and demographic, clinical, and laboratory variables in MHD patients, and attempts to identify the significant variables in the development of depressive symptoms in such patients in a single HD centre.

## Materials and methods

One hundred and forty-six ESRD patients on MHD (65 males and 81 females) in a single nephrology unit (Cardinal Tien Hospital, CTH) were enrolled in this cross-sectional study, and informed consent was secured from all the subjects. Patients deemed eligible were between 18 and 90 years of age, known to have ESRD of at least 3 months duration, and receiving MHD three times every week. This study was approved by the hospital's Health Research and Ethics Committees.

Demographic data such as age, sex, marital status, education and religious affiliation were obtained by a questionnaire. Clinical data regarding the cause of renal failure, co-morbidities, current medications and the most recent laboratory exams (full blood count, pre- and post-dialysis urea and electrolytes, taken within the past 1 month) were obtained from the patients' respective medical records. Patients found to have major infections and patients who had been taking immunosuppressive agents for at least 1 month were excluded from the study.

Body weight (post-dialysis weight), body mass index (BMI), mean blood pressure, serum high-sensitivity CRP (hs-CRP), IL-6, albumin, creatinine (Cr), total cholesterol, haematocrit, clearance of urea per dialysis (Kt/V) and normalized protein catabolism rate (nPCR) were recorded at baseline. Mid-week pre-dialysis fasting blood samples were also collected from each patient. Pre- and post-dialysis levels of serum urea were recorded for evaluation of single-pool Kt/V (Daugirda method) [13]. The nPCR was calculated from monthly kinetic modelling sessions by applying the two-blood urea nitrogen (2-BUN) method [14] to pre-dialysis BUN level, and an estimate of equilibrated post-dialysis BUN level obtained using the Daugirdas–Schmidtz equation. Body mass index (BMI in  $\text{kg}/\text{m}^2$ ) was calculated from patient height obtained at study entry and post-dialysis weight measurements obtained at monthly kinetic modelling sessions.

Co-morbidity was defined as the sum total number of concurrent illnesses and problems, such as diabetes mellitus, hypertension, congestive heart failure, coronary artery disease, cerebrovascular disease, peripheral

**Table 1.** Demographic and clinical characteristics of the patients classified according to BDI (*n* = 146)

		BDI <14 ( <i>n</i> = 78)	BDI ≥14 ( <i>n</i> = 68)	Chi-square test	P
Gender	Male	38	27	1.195	0.274
	Female	40	41		
Age	≤64 years	33	39	4.426	0.109
	65–74 years	19	16		
	≥75 years	26	13		
Spouse	Yes	54	37	3.398	0.065
	No	24	31		
Education	Below high school	44	42	3.260	0.196
	High school	19	20		
	Above high school	15	6		
Religion	Yes	68	60	0.037	0.847
	No	10	8		
Smoking	Yes	65	59	0.334	0.563
	No	13	9		
Co-morbidity <sup>a</sup>	Yes	60	61	4.183	0.041
	No	18	7		

<sup>a</sup>Co-morbidity includes diabetes mellitus, hypertension, congestive heart failure, coronary artery disease, cerebrovascular disease, peripheral vascular disease, chronic lung disease, non-skin cancer or alcohol abuse.

vascular disease, chronic lung diseases, non-skin cancer or alcohol abuse [15]. The presence of an inflammatory state was assessed by IL-6 and hs-CRP levels. Because the use of cellulose-based dialysers has been related to depression, biocompatible polysulphone dialysers (FX60; Helixone) were used on all the subjects [16].

The following biochemical parameters were checked using an AU5000 automated chemistry analyser (Olympus, Tokyo, Japan): total calcium [normal value (NV) 8.5–10.5 mg/dL], serum phosphate (Pi, NV 2.3–4.6 mg/dL) and serum albumin (NV 3.5–4.5 g/dL). Serum iPTH levels were measured by immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). Serum hs-CRP (Immulite, DPC Cirrus Inc., Los Angeles, CA, USA) and IL-6 (R&D Systems, Minneapolis,

MI, USA) were measured by the ELISA method.

The self-administered Beck Depression Inventory (BDI) was distributed by a healthcare assistant during a HD session. In the absence of standard BDI categories for patients with ESRD, the presence and/or severity of depression were categorized using BDI scores for the normal population: non-depression symptoms (scores of 0–13) and depression symptoms (14–63) [17].

#### Statistics

Continuous variables were expressed as means ± SD, and categorical values were expressed in percentages. Two group differences were analysed by *t*-test and Fisher's exact test, and  $\chi^2$  analysis was used to analyse categorical data. Pearson correlations were derived to evaluate for possible correlations between biological markers and symptoms of depression. Linear regressions were used to analyse the role of biological parameters on depression. Multivariate stepwise forward logistic regression analysis was used to determine the independent risk factors for depression. Significance was defined as *P* < 0.05. Statistical analyses were performed using

**Table 2.** Laboratory characteristics of the patients stratified according to BDI (*n* = 146)

	BDI <14 ( <i>n</i> = 78)	BDI ≥14 ( <i>n</i> = 68)	P
Haematocrit (%)	30.8 ± 3.5	30.2 ± 4.9	0.412
Haemoglobin (g/dL)	11.0 ± 7.5	10.0 ± 1.6	0.267
Blood urea nitrogen (mmol/L)	24.6 ± 7.4	25.8 ± 7	0.337
Creatinine (umol/L)	892.8 ± 195	954.7 ± 221	0.106
Interleukin-6 (pg/mL)	6.89 ± 1.65	8.0 ± 1.55	<0.001
hs-CRP (mg/dL)	0.61 ± 0.73	0.74 ± 0.96	0.166
Potassium (mmol/L)	4.4 ± 0.8	4.2 ± 0.8	0.075
Calcium (mmol/L)	2.33 ± 0.2	2.28 ± 0.25	0.2
Phosphate (mmol/L)	1.58 ± 0.48	1.68 ± 0.48	0.3
Albumin (g/L)	39 ± 4	37 ± 3	0.004
Triglycerol (mmol/L)	1.44 ± 0.97	1.73 ± 1.06	0.089
Total cholesterol (mmol/L)	4.58 ± 1.11	4.22 ± 1.06	0.048
Fasting plasma glucose (mmol/L)	7.2 ± 3.4	7.7 ± 4.4	0.47
Kt/V	1.45 ± 0.4	1.36 ± 0.3	0.117
Urea reduction ratio	74.1 ± 11.5	72.7 ± 8.09	0.389
Ferritin (µg/L)	486.4 ± 466.7	500.7 ± 430	0.858
Iron saturation (fraction saturation, %)	0.32 ± 0.12	0.31 ± 0.14	0.676
Intact-parathyroid hormone (ng/L)	496.5 ± 520.5	431.3 ± 440	0.419
nPCR (g/kg/day)	1.2 ± 0.4	2.8 ± 13.3	0.342
Body mass index (kg/m <sup>2</sup> )	22.4 ± 3.6	22.5 ± 3.8	0.931

Data are given as mean ± standard deviation.

**Table 3.** Correlates of BDI and multiple variance in MHD patients (Pearson's correlation)

Variables	<i>r</i>	P
Albumin	-0.281	<0.05
IL-6	0.466	<0.001
hs-CRP	0.358	0.166
K	-0.111	0.181
Ca	-0.067	0.425
P	0.079	0.343
Uric acid	0.049	0.561
Hb	-0.042	0.617
TG	0.122	0.143
T-Chol	-0.166	<0.05
Glucose	0.075	0.368
Kt/V	-0.188	<0.05
URR	-0.206	<0.05
Ferritin	0.074	0.372
TSAT	0.059	0.482
IPTH	-0.081	0.330
nPCR	0.098	0.241
Months on HD	-0.126	0.129
Disposable income	-0.059	0.481




Fig. 1. Correlations between BDI scores and (a) Kt/V values, (b) serum albumin levels and (c) serum IL-6 levels.

the Statistical Package for the Social Sciences, version 17.0 (SPSS Inc., Chicago, IL, USA).

## Results

The mean age of the 146 participants was  $63.8 \pm 15.2$  years (range 18–94 years); 55.5% of whom were women. All the patients had been on MHD for 0.3–22.5 years (mean  $\pm$  SD =  $4.9 \pm 4.4$  years duration). A BDI cut-off score of  $\geq 14$  was used to determine whether any patient had symptoms of depression. The mean BDI score was  $21.5 \pm 7.6$  in the group with symptoms of depression ( $n = 68$ , 46.6%) and  $6.8 \pm 3.6$  in the group without symptoms of depression ( $n = 78$ ).

Comparisons of the demographic and laboratory data for the patients with and without symptoms of depression are shown in Tables 1 and 2, respectively. No sex preponderance was observed in patients with BDI scores  $\geq 14$  (50.6% in females vs. 41.5% for males,  $P = 0.27$ ). Likewise, there were no statistically significant differences in age, sex, smoking habits or clinical characteristics. However, patients who had symptoms of depression were more likely to have co-morbid states (60/78 vs. 61/68,  $P < 0.05$ , Table 1).

Table 2 shows that there were no significant differences in BMI, NPCR, Kt/V, serum ferritin, or iPTH in patients with and without depression. However, patients with symptoms of depression had higher levels of serum IL-6 ( $6.89 \pm 1.65$  vs.  $8.0 \pm 1.55$  pg/mL,  $P < 0.001$ ) and lower levels of serum albumin ( $39 \pm 4$  vs.  $37 \pm 3$  g/L,  $P < 0.005$ ) and total cholesterol ( $4.58 \pm 1.11$  vs.  $4.22 \pm 1.06$  mmol/L,  $P < 0.005$ ). With regard to the role of adequate dialysis, we found no significant difference in Kt/V and hs-CRP values between the two patient groups.

Upon analysis of correlations between BDI and other variables, BDI was found to be significantly correlated with levels of albumin ( $P = 0.001$ ), IL-6 ( $P < 0.001$ ), total cholesterol ( $P = 0.045$ ), URR ( $P = 0.013$ ) and Kt/V ( $P = 0.023$ ) (Table 3). As shown in Figure 1, the BDI correlated significantly with Kt/V ( $r = -0.19$ ;  $P < 0.05$ ), serum albumin ( $r = -0.28$ ;  $P < 0.005$ ) and serum IL-6 ( $r = 0.47$ ;  $P < 0.001$ ), respectively. There was a trend towards a negative correlation between IL-6 and albumin levels, but this did not reach statistical significance.


Although numerous demographic, clinical and laboratory variables correlated with BDI in univariate analysis, multivariate stepwise forward logistic regression analysis showed only a direct correlation between BDI and IL-6 [ $P = 0.001$ , OR = 1.537 (95% CI = 1.18–1.99)] and between BDI and

**Table 4.** Independent risk factors for depression in MHD patients based on logistic regression analysis


	B <sup>a</sup>	Standard error	Odds ratio	95% CI	P-value
Age	-0.41	0.015	0.96	0.932–0.989	0.007
Albumin	-1.930	0.702	0.145	0.037–0.574	0.006
IL-6	0.430	0.133	1.537	1.184–1.994	0.001
Co-morbidities	1.278	0.612	3.589	1.081–11.919	0.037

CI, confidence interval.

<sup>a</sup>Coefficient for the constant.



**Fig. 2.** The prevalence of depression was significantly lower in patients aged  $\geq 75$  compared with the patients  $\leq 64$  years old (13/39 = 33.3% vs. 39/72 = 54.2%,  $P < 0.05$ ).



**Fig. 3.** The percentage of monthly disposable income more than TWD 10 000 was similar in patients aged  $\geq 75$  compared with the patients aged  $\leq 64$  (23/39 = 58.79% vs. 37/72 = 51.39%,  $P = 0.636$ ).

co-morbidities [ $P = 0.037$ , OR = 3.584 (95% CI = 1.08–1.99)]. There was an inverse correlation between BDI and albumin [ $P = 0.006$ , OR = 0.145 (95% CI = 0.037–0.574)] and between BDI and age [ $P = 0.007$ , OR = 0.96 (95% CI = 0.932–0.989)] (Table 4).

Since logistic regression showed a negative correlation between BDI and age, we divided the patients into three age groups, namely  $\leq 64$  years, 65–74 years and  $\geq 75$  years, to determine the correlation between age and symptoms of depression. The prevalence of depression was significantly lower for patients aged  $\geq 75$  years compared with those  $\leq 64$  years (33.3% vs. 54.2%,  $P < 0.05$ ) (Figure 2), but there was no significant difference with regard to the percentage of personal monthly disposable income at or above TWD >10 000 (USD 312.5) in these two patient groups (58.79% vs. 51.39%,  $P = 0.636$ ) (Figure 3). However, those patients aged  $\leq 64$  years had higher levels of serum albumin ( $3.93 \pm 0.32$  vs.  $3.67 \pm 0.37$  g/day,  $P \leq 0.001$ ) and lower number of co-morbid diseases ( $2.3 \pm 1.5$  vs.  $3.0 \pm 1.0$  g/day,  $P \leq 0.05$ )

compared with patients aged  $\geq 75$  years. However, both groups had similar nPCR values ( $1.24 \pm 0.32$  vs.  $1.19 \pm 0.51$ ,  $P = 0.58$ ).

## Discussion

Depression is common among patients on MHD, and we found that 46.6% of our patients had symptoms of depression. Worldwide, depression is  $\sim 1.5$  to two times more common in women than men, and its initial onset peaks during the childbearing years [18–20]. This female preponderance is known to persist into older age, but in our patients, there was no significant role for a difference in gender that might have any influence on symptoms of depression in MHD patients.

It is well known that personal disposable income or financial security is an important factor influencing depression [21]. Patients who have been on MHD for quite a long time or who are relatively financially secure may be less likely to present with symptoms of depression [7,22]. Since 1995, the Taiwan Bureau of National Health Insurance (BNHI) has provided a full healthcare coverage for patients on MHD, including an exemption for payment of the monthly health insurance fee. This 'zero out-of-pocket' policy has significantly benefited MHD patients. Our data show no statistically significant difference with regard to personal disposable income for elderly patients (age  $\geq 75$  years) as well as for patients  $\leq 64$  years old, which suggests that economic status may not have a significant role in symptoms of depression.

A state of advanced chronic kidney disease and dialysis are known to be associated with a state of chronic inflammation, as evidenced by either elevated levels of various pro-inflammatory cytokines or increased levels of acute-phase proteins [12,23–25]. This state of chronic inflammation is also seen in patients with MHD and concurrent hyperhomocysteinaemia [26–29] or secondary hyperparathyroidism [10]. Depression is independently associated with markedly increased risks of morbidity and mortality [2,15,30–32]. There is numerous evidence to suggest that CRP and its precursor, IL-6, are positively associated with an increased incidence and severity of depression. We have also shown that patients with depression symptoms have higher levels of serum IL-6.

With regard to the role of the dialyser, it has been reported that the prevalence of depression is lower in MHD patients who are dialysed using more biocompatible polysulphone dialysers [16]. Since all of our patients were on this type of dialyser, the dialyser itself did not have any significant role in this study. Our results revealed the levels of IL-6 were not significantly correlated with Kt/V, which suggests that with adequate dialysis (average Kt/V in non-depression was  $1.36 \pm 0.3$  vs. in depression was  $1.45 \pm 0.4$ ,  $P = 0.017$ ) and use of biocompatible dialysers, the dialysis dosage per se does not modulate serum IL-6 levels. However, the BDI scores were significantly correlated with IL-6. Multivariate stepwise forward logistic regression analysis showed a direct correlation between BDI scores and levels of serum IL-6, which suggests that IL-6 may play a significant role in the development of symptoms of depression in

our MHD patients. A negative correlation between BDI and Kt/V implies that higher doses of dialysis may be associated with decreased symptoms of depression. Thus, levels of IL-6 and adequacy of dialysis were strongly associated with depression in our MHD patients.

Our study found that patients with BDI scores  $\geq 14$  have lower levels of serum albumin compared with patients with BDI scores  $< 14$ . In states of inflammation, nuclear factor kappa B (NF- $\kappa$ B) causes decreased albumin gene expression, which leads to a decreased rate of albumin synthesis [33,34], and a reduced serum albumin concentration. Thus, we suspect that depression may be closely associated with inflammation and malnutrition [35].

Dialysis exacts both a physical and mental toll on patients, and chronic illness overshadows any other condition that might affect the severity of depression. As has been previously reported, we found that depressed patients often have more co-morbid states than patients without depression [15]. Despite the high prevalence of co-morbidities in older MHD patients, the prevalence of depression showed a tendency to decrease with age. Since our MHD patients had comparable economic status regardless of age, this finding may reflect a better adjustment to the psychological burden of dialysis on the part of elderly MHD patients [36]. Logistic regression analysis revealed that co-morbidity is the most important independent risk factor (OR 3.58, 95% CI 1.08–1.19,  $P < 0.05$ ) for depression in our MHD patients. These underline the importance of treating co-morbidities in MHD patients.

In conclusion, patients on MHD with symptoms of depression may have higher serum IL-6 and lower serum albumin levels. Dialysis dosage is closely correlated to the severity of depression symptoms. Elderly patients (aged  $\geq 75$  years) had lower prevalence of depression which was not apparently related to economic status. Factors including co-morbid conditions, serum IL-6, albumin and age may play significant roles in predicting which patients may be predisposed to develop symptoms of depression. Whether attenuation of inflammation and amelioration of nutritional status, even in the presence of co-morbid illnesses, may alleviate symptoms of depression in MHD patients deserves further.

*Conflict of interest statement.* None declared.

## References

1. Kimmel PL, Peterson RA. Depression in end-stage renal disease patients treated with hemodialysis: tools, correlates, outcomes, and needs. *Semin Dial* 2005; 18: 91–97
2. Lopes AA, Bragg J, Young E *et al.* Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. *Kidney Int* 2002; 62: 199–207
3. Kimmel PL. Depression in patients with chronic renal disease: what we know and what we need to know. *J Psychosom Res* 2002; 53: 951–956
4. Kimmel PL, Peterson RA. Depression in patients with end-stage renal disease treated with dialysis: has the time to treat arrived? *Clin J Am Soc Nephrol* 2006; 1: 349–352
5. Drayer RA, Piraino B, Reynolds CF 3rd *et al.* Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. *Gen Hosp Psychiatry* 2006; 28: 306–312
6. Jablonski A. The multidimensional characteristics of symptoms reported by patients on hemodialysis. *Nephrol Nurs J* 2007; 34: 29–37

7. Son YJ, Choi KS, Park YR *et al.* Depression, symptoms and the quality of life in patients on hemodialysis for end-stage renal disease. *Am J Nephrol* 2009; 29: 36–42
8. Dervisoglu E, Kir HM, Kalender B *et al.* Depressive symptoms and proinflammatory cytokine levels in chronic renal failure patients. *Nephron Clin Pract* 2008; 108: c272–c277
9. Simic Ogrizovic S, Jovanovic D, Dopsaj V *et al.* Could depression be a new branch of MIA syndrome? *Clin Nephrol* 2009; 71: 164–172
10. Lu KC, Tseng CF, Wu CC *et al.* Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism. *Blood Purif* 2006; 24: 423–430
11. Bossola M, Ciciarelli C, Conte GL *et al.* Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. *Gen Hosp Psychiatry* 2010; 32: 125–131
12. Barreto DV, Barreto FC, Liabeuf S *et al.* Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. *Kidney Int* 2010; 77: 550–556
13. Buur T. Two-sample hemodialysis urea kinetic modeling: validation of the method. *Nephron* 1995; 69: 49–53
14. Daugirdas JT, Schneditz D. Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flow but not by conventional two pool urea kinetic analysis. *ASAIO J* 1995; 41: M719–M724
15. Hedayati SS, Bosworth HB, Briley LP *et al.* Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. *Kidney Int* 2008; 74: 930–936
16. Hsu HJ, Chen CK, Wu MS. Lower prevalence of depression in hemodialysis patients who use polysulfone dialyzers. *Am J Nephrol* 2009; 29: 592–597
17. Cohen SD, Norris L, Acquaviva K *et al.* Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. *Clin J Am Soc Nephrol* 2007; 2: 1332–1342
18. Weissman MM, Olfson M. Depression in women: implications for health care research. *Science* 1995; 269: 799–801
19. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians–American Society of Internal Medicine. *Ann Intern Med* 2000; 132: 738–742
20. Blazer DG, Kessler RC, McGonagle KA *et al.* The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. *Am J Psychiatry* 1994; 151: 979–986
21. Takaki J, Nishi T, Shimoyama H *et al.* Possible interactive effects of demographic factors and stress coping mechanisms on depression and anxiety in maintenance hemodialysis patients. *J Psychosom Res* 2005; 58: 217–223
22. Lopes AA, Albert JM, Young EW *et al.* Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. *Kidney Int* 2004; 66: 2047–2053
23. Caglar K, Peng Y, Pupim LB *et al.* Inflammatory signals associated with hemodialysis. *Kidney Int* 2002; 62: 1408–1416
24. Cavaillon JM, Poignet JL, Fitting C *et al.* Serum interleukin-6 in long-term hemodialyzed patients. *Nephron* 1992; 60: 307–313
25. Kato A, Odamaki M, Takita T *et al.* Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. *Kidney Int* 2002; 61: 1143–1152
26. Chang TY, Chou KJ, Tseng CF *et al.* Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients. *Curr Med Res Opin* 2007; 23: 1879–1886
27. Ducloux D, Bresson-Vautrin C, Kribs M *et al.* C-reactive protein and cardiovascular disease in peritoneal dialysis patients. *Kidney Int* 2002; 62: 1417–1422
28. Suliman M, Stenvinkel P, Qureshi AR *et al.* The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrol Dial Transplant* 2007; 22: 209–217
29. Lange H, Suryapranata H, De Luca G *et al.* Folate therapy and in-stent restenosis after coronary stenting. *N Engl J Med* 2004; 350: 2673–2681
30. Hedayati SS, Minhajuddin AT, Toto RD *et al.* Prevalence of major depressive episode in CKD. *Am J Kidney Dis* 2009; 54: 424–432
31. Hedayati SS, Grambow SC, Szczech LA *et al.* Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. *Am J Kidney Dis* 2005; 46: 642–649
32. Troidle L, Watnick S, Wuerth DB *et al.* Depression and its association with peritonitis in long-term peritoneal dialysis patients. *Am J Kidney Dis* 2003; 42: 350–354
33. Guttridge DC, Mayo MW, Madrid LV *et al.* NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. *Science* 2000; 289: 2363–2366
34. Moshage HJ, Janssen JA, Franssen JH *et al.* Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. *J Clin Invest* 1987; 79: 1635–1641
35. Mak RH, Cheung W, Cone RD *et al.* Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. *Nat Clin Pract Nephrol* 2006; 2: 527–534
36. Chilcot J, Wellsted D, Farrington K. Screening for depression while patients dialyse: an evaluation. *Nephrol Dial Transplant* 2008; 23: 2653–2659

Received for publication: 2.4.10; Accepted in revised form: 21.6.10